WANY
LCTX icon

Wealthspire Advisors (New York)’s Lineage Cell Therapeutics LCTX Stock Holding History

Wealthspire Advisors (New York)’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-88
Closed -$149 – 2059
2025
Q3 		$149 Buy
+88
New +$104 ﹤0.01% 2973

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wealthspire Advisors (New York)'s LCTX Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Lineage Cell Therapeutics (LCTX) in Q4 2025, closing a stake of 88 shares — an estimated $149 sold.

Wealthspire Advisors (New York) first reported a position in LCTX in Q3 2025 and held it in 1 quarter. The position peaked at $149 in Q3 2025. 123 funds tracked by Wall St. Rank hold LCTX as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Lineage Cell Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 88 Lineage Cell Therapeutics shares in Q4 2025, an estimated $149.
  • Wealthspire Advisors (New York) first reported a position in Lineage Cell Therapeutics in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Lineage Cell Therapeutics position peaked at $149 in Q3 2025.
  • 123 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.